• Home
  • Human Cancer Proteome Project

human Cancer Proteome Project (Cancer-HPP)

The Human Cancer Proteome Project (Cancer-HPP) is an international initiative organized by HUPO whose key objective is to decipher the human cancer proteome through a coordinated effort by cancer proteome researchers around the world. The goal is to map the entire human cancer proteome to disclose tumor biology and drive improved diagnostics and treatment of cancer

Click here to read the 2017 Cancer-HPP report. 

Main activities:

  • Network cancer proteome researchers by organizing dedicated sessions/workshops during the annual HUPO conference that showcase the state-of-the-art in cancer proteomics
  • Bring cancer proteome researchers together to delineate the human cancer proteome in all its complex facets (tumor (sub)types, clinical characteristics) 
  • Foster high-quality cancer proteomics research by providing guidelines and/or referring to best practices for specimen collection and data acquisition
  • Seek synergy with (inter)national large-scale cancer proteomics efforts
  • Advocate cancer proteomics in the larger cancer research community, and with funding/ policy makers

Cancer-HPP steering committee:

  • Hui Zhang (Chair), John Hopkins University, Baltimore
  • Edouard Nice (Co-chair), Monash University, Australia
  • Connie Jimenez (Co-chair), VU University Medical Center, Amsterdam
  • Chris Kinsinger (NIH/NCI)

Cancer-HPP partners:

Cancer HPP partners with NCI's Clinical Proteome Tumor Analysis Consortium (CPTAC).

Major goal for the coming 5 years:

  • Delineate cancer proteomes versus matched normal/ premalignant
  • Identify tumor-type specific signatures by comparison of multiple tumor types through data sharing and analysis
  • Deposition of raw data of cancer proteomics datasets after publication in the public domain (eg., Proteome Exchange) to enable meta-analyses

Highlights in the field of cancer proteomics:

  1. The proteomic landscape of several major human tumors (breast, colorectal, and ovarian cancer) was analyzed by the NCI-Cancer Proteomics Tumor Analysis Consortium (CPTAC) and published in high impact papers.  Importantly, all data are publicly available
  2. CPTAC goes international: agreements in place to characterize additional tumors in Australia, Canada, Germany, Japan, South Korea, Switzerland, Taiwan, and United States

Further reading:

1. Summary of B/D HPP in 2015 HUPO
    Jennifer E Van Eyk, Fernando Jose Corrales, Ruedi Aebersold, Ferdinando Cerciello, Eric W Deutsch, Paola Roncada, Jean-Charles Sanchez, Tadashi Yamamoto, Pengyuan Yang, Hui Zhang, Gilbert S Omenn Highlights of the Biology and Disease-driven Human Proteome Project, 2015-2016. Journal or Proteome Research, DOI: 10.1021/acs.jproteome.6b00444 Publication Date (Web): August 30, 2016.

    2. NIH Bio-specimens 

    National Cancer Institute (NCI) 

    Specimen resource locator https://specimens.cancer.gov/

    3.  CPTAC publications

    Zhang, H, Liu T, Zhang Z, Payne S. et al (2016) Integrated proteogenomic characterization of human high grade serous ovarian cancer. Cell. http://www.cell.com/cell/home

    Mertins P, et al (2016) Proteogenomic Analysis of Human Breast Cancer Connects Genetic Alterations to Phosphorylation NetworksNature . http://www.nature.com/nature.

    Zhang B, Wang J, Wang X, Zhu J, et al. (2014) Proteogenomic characterization of human colon and rectal cancer Nature 513 (7518): 382-7. 


    Cancer-HPP Mailing List:

    Are you involved in Cancer Research? Interested in the latest initiatives of the Cancer-HPP? If so, subscribe to the Cancer-HPP mailing list to receive initiative updates, news and meeting details.

    The Cancer-HPP key aims are to:

    1. Characterize proteomes, proteome forms, and protein networks from different cancers and the matched non-cancers through coordinated efforts of specimen collections and data acquisitions.

    2. Identify cancer-specific proteins, protein forms, or protein networks from each cancer type and cancer-type-specific proteins, protein forms, and protein networks by comparison of multiple cancer types through data deposition, sharing, and data analysis.

    3. Determine the protein-specific or protein-isoform-specific changes of cancer through the correlation studies of genomic and proteomic data through the comparison to the existing genomic data or the genomic data collected from each specimen.

    4. Develop targeted assays to measure protein- or protein-form-specific changes for each tumor type to support the analysis of complex biological networks or clinical specimens underlying different disease processes.

    5. Disseminate assays to the discovery labs to apply the targeted assays to the specimens from discovery specimens to verify the changes from discovery phase.

    6. Validate the protein, protein forms, or protein network changes in independent specimens.

    Click here to subscribe

    Copyright 2016 - HUPO

    Powered by Wild Apricot Membership Software